Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Chronic Lymphocytic Leukemia Clinical Trials

A listing of Chronic Lymphocytic Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (58) clinical trials

Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant

OBJECTIVES: Primary - Determine the one- and two-year survival of patients with hematologic malignancies treated with a nonmyeloablative conditioning regimen comprising fludarabine, cyclophosphamide, and total-body irradiation followed by umbilical cord blood transplantation and post-transplant immunosuppression comprising sirolimus and mycophenolate mofetil. Secondary - Determine the six-month nonrelapse mortality of patients treated ...

Phase

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

OBJECTIVES: Primary - Determine the 1-year survival of patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine, cyclophosphamide, and fractionated total-body irradiation. Secondary - Determine the incidence of transplant-related mortality at 6 months after UCBT. - Evaluate the pattern of chimerism ...

Phase

Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation

This is a non-randomized, phase II protocol to evaluate engraftment of cord blood after treatment with myeloablative conditioning of fludarabine, total body irradiation and cyclophosphamide. All patients will receive tacrolimus and mycophenolate mofetil as prophylaxis for graft-vs-host disease. Conditioning Regimen: - Days -10 to -7: Fludarabine 30mg/m2/day IV - Days ...

Phase

T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts

To participate in this study, the subject will need to have a central line (a thin plastic catheter or tube that is placed during surgery into one of the large veins in the neck or chest). Also before treatment can begin, we will test the subject's blood for viruses which ...

Phase

Cyclophosphamide Fludarabine Total-Body Irradiation and Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer or Other Disease

OBJECTIVES: Primary - Determine, preliminarily, the efficacy of double-unit umbilical cord blood (UCB) transplantation (UCBT) in patients with hematologic malignancy. Secondary - Determine the incidence and rate of donor-derived neutrophil and platelet recovery in these patients. - Determine the contribution of each unit of UCB to initial and sustained engraftment ...

Phase

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

OBJECTIVES: - Determine the overall survival rate at day 200 in patients with hematologic cancers or other diseases who undergo allogeneic peripheral blood stem cell transplantation using the CliniMACS® CD34 Reagent System for T-cell depletion followed by delayed T-cell add-back. - Determine the safety of this regimen, in terms of ...

Phase

Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma Multiple Myeloma or Chronic Lymphocytic Leukemia

OBJECTIVES: - Determine if allogeneic stem cell transplantation using unrelated matched or related haploidentical donor bone marrow or unrelated matched cord blood results in timely, complete, and durable engraftment in patients with previously treated lymphoma, multiple myeloma, or chronic lymphocytic leukemia. - Determine the incidence and grade of acute and ...

Phase

Multi-center Trial of Revlimid and Rituximab for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

The CLL Research Consortium (CRC) is conducting a two-arm, multi-center phase II trial of Revlimid® and rituximab for the first-line treatment of patients with CLL. Revlimid® (lenalidomide) a derivative of thalidomide with immune-modulating properties. Revlimid® is FDA approved for treatment of relapsed multiple myeloma and 5q- myelodysplastic syndrome. Revlimid® has ...

Phase

Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])

The standard treatment in many disorders of the bone marrow is high dose chemotherapy and whole-body radiation treatment followed by the stem cell transplant. This type of transplant not only suppresses or kills off the immune system, but is very toxic to the bone marrow. This study uses a chemotherapy ...

Phase

Administration of Jakafi (Ruxolitinib) to Patients With Previously Untreated High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

If you agree to take part in this study, you will take ruxolitinib pills by mouth 2 times each day. The study doctor will tell you which dose you are taking. Length of Study Participation: You may receive ruxolitinib for up to 3 years. If the study doctor thinks it ...

Phase